Captopril

WILMINGTON, N.C., May 14, 2024 /PRNewswire/ -- CardioPharma Inc. (the "Company"), a specialty pharmaceutical company focused on drug development for cardiovascular diseases, announced that on August 29, 2023, the United States Patent and Trademark Office ("USPTO") issued US Patent 11,737,988 B2 entitled "Anti-Hypertensive and Cholesterol-Lowering Fixed-Dose Combination and Method of Manufacture." Additional patents covering the subject matter of the '988 Patent have been granted in South Africa in 2022 and Australia, Armenia, Belarus, and the Russian Federation in 2024. Three further patents have been accepted in Canada, New Zealand, and Israel and will issue in the near future. In addition to the foregoing, CardioPharma is pursuing additional patents in major markets throughout the world, all of which together will bolster CardioPharma's global presence for the products covered by the patent grants. The 20-year term for all of the patents runs through April 17, 2039. CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma (), Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for doctors and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit . Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. Contact: [email protected] SOURCE CardioPharma, Inc.

PROTECT 3 study showed improvement in clinical outcomes, revascularisation, and safety, compared to the PROTECT 2 Randomized Controlled Trial Impella 2.5 Pump in Heart Illustration. (Credit: ABIOMED.) Abiomed has announced that the use of its Impella heart pumps in PROTECT 3 and Restore EF studies showed superior outcomes for patients at high-risk of percutaneous coronary interventions (PCI). Approved by the US FDA, the Impella 2.5 and Impella CP devices are designed to treat certain advanced heart failure patients undergoing elective and urgent PCI. Also, Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with SmartAssist are also approved in the US, to treat cardiomyopathy patients. PROTECT 3 study showed improvement in 90-day clinical outcomes, revascularisation, and safety, compared to the PROTECT 2 Randomized Controlled Trial (RCT). In the PROTECT 2 RCT, use of Impella reduced a 29% relative risk in MACCE, compared to use of intra-aortic balloon pump (IABP). The researchers analysed PROTECT 3 participants who would have qualified for PROTECT 2 RCT, and compared them to PROTECT 2 participants. Patients in the PROTECT 3 study showed improvement in MACCE rates in 90 days, compared to PROTECT 2 patients, with a relative risk reduction of 31%. The study showed superior complete revascularisation, 78% less hypotension, and improved in-hospital safety, with fewer bleeding complications requiring transfusion. PROTECT 3 study lead investigator Jeff Moses said: “Advancement in technology, along with best practice learnings and operator experience has led to improvements in patient outcomes in contemporary practice. “These two studies expand upon prior research and demonstrate a clinical benefit in today’s broader patient population.” The Restore EF prospective study showed that use of contemporary best practices with Impella has showed improved outcomes in 251 patients at elevated risk of PCI. The improvements include left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms in rural, urban, community hospital and academic centres settings. Improvement in LVEF from baseline to 90-day follow-up is the study’s primary endpoint. Furthermore, the study showed reduction of heart failure symptoms with 76% reduction in NYHA classification III/IV, and anginal symptoms with 97% reduction in CCS classification III/IV.